当前位置: 首页 > 期刊 > 《世界中医药》 > 201912
编号:13546101
推进真实世界研究的透明化(6)
http://www.100md.com 2019年6月15日 《世界中医药》 201912
     [25]Gamble C,Krishan A,Stocken D,et al.Guidelines for the Content of Statistical Analysis Plans in Clinical Trials[J].JAMA,2017,318(23):2337-2343.

    [26]张颖,王丽琼,费宇彤,等.统计分析计划(SAP)报告指南的解读及其对中医药临床研究的启示[J].中医杂志,2019,60(5):30-35.

    [27]高培,王杨,罗剑锋,等.基于真实世界数据评价治疗结局研究的统计分析技术规范[J].中国循证医学杂志,2019,19(7):787-793.

    [28]Langan SM,Schmidt SA,Wing K,et al.The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology(RECORD-PE)[J].BMJ,2018,363:k3532.

    [29]Moher D,Liberati A,Tetzlaff J,et al.Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement[J].BMJ,2009,339:b2535.

    [30]von Elm E,Altman DG,Egger M,et al.The Strengthening the Reporting of Observational Studies in Epidemiology(STROBE)statement:guidelines for reporting observational studies[J].Lancet,2007,370(9596):1453-1457.

    [31]Benchimol EI,Smeeth L,Guttmann A,et al.The REporting of studies Conducted using Observational Routinely-collected health Data(RECORD)statement[J].PLoS Med,2015,12(10):e1001885.

    [32]吳泰相,卞兆祥,李幼平,等.临床试验原始数据透明化与共享:关于医学研究伦理的哲学命题及其对临床试验的意义[J].中国循证医学杂志,2018,18(6):538-542.

    (2019-11-10收稿 责任编辑:徐颖), 百拇医药(金鑫瑶 郑文科 张俊华 孙鑫 姚晨 詹思延 谢雁鸣 刘建平 胡镜清 何丽云 田金)
上一页1 2 3 4 5 6